Dr Reddys Laboratories Ltd News

Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Top 10 pharma firms sustain volume growth as smaller rivals struggle

The top 10 in August included Sun Pharma, Cipla, Abbott, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Intas Pharmaceuticals, Lupin, Zydus Lifesciences and Dr Reddy's Laboratories

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

The deal comes months after India's drug regulator approved Qdenga for use in both children and adults, making it the first dengue vaccine cleared for the country

'India began drug discovery before China, but China has moved years ahead'

India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy

Indian drugmakers in no rush to shift to US despite tariff threat

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Sensex, Nifty gain 2% in July led by IT; 50% of BSE 500 stocks underperform

Among sectoral indices, the BSE IT surged 16% followed by Consumer Durables (9%), Realty (8%) and Auto (6%). On the flip side, Capital Goods and Power indices declined 7% and 6%, respectively.

Laurus Labs extends rally, up 97% from Feb low; tops Dr Reddy's market-cap

Laurus Labs quoted higher for the fourth straight day, surging 15% in this period after delivering record quarterly revenue with expanded profitability and continued portfolio transformation.

The reform booster shot that transformed India into pharmacy of the world

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Dr Reddy's may underperform on growth, margin worries after muted Q1

North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook

Dr Reddy's Labs shares tank 9% to 52-week low after Q1 show. Time to sell?

Brokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Dr Reddy's Labs Q1FY27 results: Net profit plunges 69% to ₹443 crore

The drugmaker attributed the sharp earnings decline to a one-time semaglutide provision and the end of its lenalidomide agreement, while retaining its FY27 guidance

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5%

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Dr Reddy's drops 4% on semaglutide setback; should investors buy the dip?

The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API used in the product

Stocks to Watch today: TCS, Maruti, JSW Steel, JK Tyre, Federal Bank & more

Stocks to watch today: TCS, Maruti Suzuki, JSW Steel, JK Tyre, Federal Bank, AU SFB, SAIL, Nalco, NLC India, Anand Rathi Wealth, JSW Steel, Cummins India, among others, will be in focus today

Dr Reddy's to miss annual semaglutide supply target over API quality issue

Drugmaker says it will supply 6-7 million pens in the last two quarters of FY27 and restart production by November after resolving the API-related quality issue

Dr Reddy's delays semaglutide supplies over active ingredient quality issue

Drugmaker said certain batches of semaglutide failed to meet quality specifications, prompting a delay in commercial supplies, while maintaining there is no impact on patient safety

Dr Reddy's plunges 6% on semaglutide batch quality, supply delay concerns

Dr Reddy's informed stock exchanges that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient used in the product.

Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why

Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.